# A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma

> **NCT01353482** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University College, London**

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Vorinostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01353482
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** UCL CTC were informed by Merck Sharp \& Dohme on 22.08.11 that support for the trial had been withdrawn in light of results from another trial with trial drug.
- **Last updated:** 2012-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01353482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01353482, "A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01353482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*